Form 4: Vaxcyte COO Sells Shares Under 10b5-1 Plan

Vaxcyte, Inc. reports that Chief Operating Officer Jim Wassil sold a significant number of company shares through a pre-arranged trading plan.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., executed a series of stock sales on June 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on December 9, 2025.
• A total of 1,949 shares were sold at a weighted-average price of $49.404, with individual sales ranging from $49.03 to $49.93.
• Additionally, 301 shares were sold at a weighted-average price of $50.257, with individual sales ranging from $50.205 to $51.01.
• Following these transactions, Wassil beneficially owns 158,795 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a negative signal, the execution under a Rule 10b5-1 plan indicates a pre-determined strategy rather than a reaction to current company performance.

Negatives

• Insider selling activity, particularly by a high-ranking executive like the COO, can sometimes be perceived negatively by the market, although in this case it was executed under a pre-planned Rule 10b5-1 trading plan.

Risks

• The Rule 10b5-1 trading plan is designed to provide an affirmative defense against allegations of insider trading, but the execution of such plans can still be subject to market interpretation and scrutiny.
• While the plan was established in December 2025, the actual sales occurring in June 2026 might coincide with periods of market volatility or company-specific news, potentially influencing investor perception.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event in the biotechnology sector. Investors often monitor such transactions for insights into executive confidence, though the pre-planned nature of these sales mitigates concerns about immediate non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a plan, with caution, though the pre-planned nature mitigates direct concerns about insider trading.
• Employees: The COO's stock sales might influence employee sentiment, depending on broader company performance and communication.
• Management: Reinforces the established procedures for executive stock transactions.

Next Steps

• Continued monitoring of Jim Wassil's beneficial ownership following these transactions.
• Observation of any future transactions or amendments to the Rule 10b5-1 trading plan.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Jim Wassil, COO, Beneficial Ownership